公开(公告)号：US20220227887A1

公开(公告)日：2022-07-21

申请号：US17617781

申请日：2020-06-10

Applicant: ONO PHARMACEUTICAL CO., LTD. ,  TOKUSHIMA UNIVERSITY

Inventor： Taku OKAZAKI ,  Daisuke SUGIURA ,  II-mi OKAZAKI ,  Shiro SHIBAYAMA

IPC: C07K16/46 ,  A61P37/06 ,  A61P37/08 ,  C07K16/28

Abstract: An immunosuppressant containing a bispecific molecule including a first binding site that specifically binds to LAG3 and a second binding site that specifically binds to CD3 or CD8.

公开(公告)号：US11000572B2

公开(公告)日：2021-05-11

申请号：US16671497

申请日：2019-11-01

Applicant: TOKUSHIMA UNIVERSITY

Inventor： Akihito Yamamoto ,  Minoru Ueda ,  Kohki Matsubara ,  Akio Suzumura ,  Koichi Furukawa ,  Yoshihiro Matsushita ,  Hirotaka Wakayama ,  Nobunori Takahashi ,  Shin Tsunekawa ,  Takako Izumoto

IPC: A61K38/19 ,  C12N5/0786 ,  A61K45/06 ,  A61K31/737 ,  A61K38/17

Abstract: A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.

公开(公告)号：US20200347165A1

公开(公告)日：2020-11-05

申请号：US16762221

申请日：2018-11-14

Applicant: TOKUSHIMA UNIVERSITY ,  SEKISUI CHEMICAL CO., LTD.

Inventor： Koichi UTE ,  Tomohiro HIRANO ,  Miyuki OSHIMURA ,  Yasunari KUSAKA ,  Yohei NISHIMURA ,  Misaki SENOO

IPC: C08F218/08 ,  C08F216/06

Abstract: The present invention provides a vinyl alcohol-vinyl acetate copolymer having excellent solubility and capable of providing a film having high flexibility, high mechanical strength, and high adhesion, and a method for producing a vinyl alcohol-vinyl acetate copolymer. Provided is a vinyl alcohol-vinyl acetate copolymer including a unit of vinyl alcohol and a unit of vinyl acetate, the vinyl alcohol-vinyl acetate copolymer having a triad unit chain ratio TOO of 7.5 or less, where the triad unit chain ratio TOO is obtained using the following formula (1): [ Math .  1 ] T OO = [ Vac   content ] × [ OOO   proportion ] × 2 [ VOH   content ] × [ AOO   proportion ] ( 1 ) wherein the VOH content ratio represents the amount of the unit of vinyl alcohol, the Vac content ratio represents the amount of the unit of vinyl acetate, the OOO proportion represents the proportion of a triad OOO, and the AOO proportion represents the proportion of a triad AOO.

公开(公告)号：US20200255474A1

公开(公告)日：2020-08-13

申请号：US16631141

申请日：2018-07-18

Applicant: TOKUSHIMA UNIVERSITY ,  ONCOTHERAPY SCIENCE, INC.

Inventor： Toyomasa KATAGIRI ,  Tetsuro YOSHIMARU ,  Takashi MIYAMOTO ,  Yasuhide OKAMOTO

IPC: C07K7/08 ,  A61P35/00 ,  A61K47/65

Abstract: The present invention provides peptides having a structure in which portions of a dominant-negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 are replaced by at least two stapling structures. The peptides of the present invention have excellent cell growth inhibiting activity. The cell growth inhibiting activity lasts longer, compared to a single-stapled peptide. Therefore, the peptides of the present invention have a feature suitable for clinical applications in cancer therapy.

公开(公告)号：US10711081B2

公开(公告)日：2020-07-14

申请号：US16098478

申请日：2017-05-08

Applicant: TOKUSHIMA UNIVERSITY ,  SEKISUI CHEMICAL CO., LTD.

Inventor： Koichi Ute ,  Tomohiro Hirano ,  Miyuki Oshimura ,  Yasunari Kusaka

IPC: C08F216/06 ,  C08F218/08 ,  C08F8/14 ,  C08F216/38 ,  C08F8/12 ,  B01J31/12

Abstract: The present invention provides a vinyl alcohol-vinyl acetate copolymer having excellent solubility and a method for producing a vinyl alcohol-vinyl acetate copolymer. Provided is a vinyl alcohol-vinyl acetate copolymer including a unit of vinyl alcohol and a unit of vinyl acetate, the vinyl alcohol-vinyl acetate copolymer having a randomness value R of 0.5 or higher, the randomness value R being obtained using the following equation (1): R = 1 L A + 1 L O ( 1 ) where LO represents a mean chain length of the unit of vinyl alcohol and LA represents a mean chain length of the unit of vinyl acetate.

公开(公告)号：US10669310B2

公开(公告)日：2020-06-02

申请号：US16070896

申请日：2017-01-16

Applicant: TOKUSHIMA UNIVERSITY ,  ONCOTHERAPY SCIENCE, INC.

Inventor： Toyomasa Katagiri ,  Takashi Miyamoto ,  Rie Hayashi

IPC: A61K38/10 ,  C07K7/04 ,  A61K38/00 ,  C07K7/00 ,  A61P35/00 ,  A61K38/03

Abstract: The present invention provides peptides containing a structure in which a portion of the dominant negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 is substituted with stapling structure(s). Peptides of the present invention have excellent cell growth inhibitory actions. Furthermore, their cell growth inhibitory actions continue for a longer time than the actions of peptides without stapling structures. Therefore, these peptides have features suitable for clinical applications in cancer therapy.

公开(公告)号：US10507230B2

公开(公告)日：2019-12-17

申请号：US15938839

申请日：2018-03-28

Applicant: TOKUSHIMA UNIVERSITY

Inventor： Akihito Yamamoto ,  Minoru Ueda ,  Kohki Matsubara ,  Akio Suzumura ,  Koichi Furukawa ,  Yoshihiro Matsushita ,  Hirotaka Wakayama ,  Nobunori Takahashi ,  Shin Tsunekawa ,  Takako Izumoto

IPC: A61K38/19 ,  C12N5/00 ,  C12N5/0786 ,  A61K45/06 ,  A61K31/737 ,  A61K38/17

Abstract: A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.

公开(公告)号：US09409972B2

公开(公告)日：2016-08-09

申请号：US14193362

申请日：2014-02-28

Applicant: SAISEI MIRAI CLINIC ,  TOKUSHIMA UNIVERSITY

Inventor： Yoshihiro Uto ,  Hitoshi Hori ,  Toshio Inui ,  Kentaro Kubo

IPC: A01N65/00 ,  C07K14/765 ,  A61K35/16 ,  A61K38/47

CPC classification number: C07K14/765 ,  A61K35/16 ,  A61K38/47

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with β-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract translation: 本发明的目的是提供一种药物组合物及其制备方法，其包含可用于治疗和预防诸如癌症和感染性疾病的疾病的经酶处理的人血清。 本发明涉及一种制备包含经酶处理的人血清的药物组合物的方法，包括使人血清与β-半乳糖苷酶接触的步骤，以及包含经酶处理的人血清 制备方法。

公开(公告)号：US20160178517A1

公开(公告)日：2016-06-23

申请号：US14913296

申请日：2014-08-21

Applicant: TOKUSHIMA UNIVERSITY

Inventor： Yoshihiro Deguchi ,  Takahiro Kamimoto

IPC: G01N21/61 ,  G01N21/3504 ,  G01N21/31 ,  G01K11/18 ,  G01N21/39

CPC classification number: G01N21/61 ,  G01J3/427 ,  G01J3/4338 ,  G01J5/0014 ,  G01J5/601 ,  G01K11/00 ,  G01K11/18 ,  G01N21/3151 ,  G01N21/3504 ,  G01N21/39 ,  G01N2021/399

Abstract: A gas analyzing apparatus includes first and second laser sources (11, 12) that output first and second laser lights, a laser controller (14) that controls the first and second laser sources to vary wavelengths of the first and second laser lights in the respective predetermined wavelength ranges, an optical multiplexer (15, 17) that multiplexes the first and second laser lights to transmit the multiplexed laser light to a target gas, an optical receiver (19) that receives the laser light transmitted through the target gas, and an analyzer (23) that analyzes a temperature and/or a concentration of the target gas based on an electric signal output from the optical receiver. While varying the wavelengths of the laser lights, the laser controller (14) controls amplitudes of the first and second laser lights to differ from each other and varies intensities of the first and second laser lights in the opposite direction.

Abstract translation: 气体分析装置包括输出第一和第二激光的第一和第二激光源（11,12），控制第一和第二激光源以改变相应的第一和第二激光的波长的激光控制器（14） 预定的波长范围，多路复用第一和第二激光以将复用的激光发射到目标气体的光复用器（15,17），接收透过目标气体的激光的光接收器（19），以及 分析器（23），其基于从光接收器输出的电信号来分析目标气体的温度和/或浓度。 在激光的波长变化的同时，激光控制器（14）控制第一和第二激光的振幅彼此不同，并且使第一和第二激光的强度在相反方向上变化。

公开(公告)号：US09351949B2

公开(公告)日：2016-05-31

申请号：US14414578

申请日：2013-06-03

Applicant: SBI PHARMACEUTICALS CO., LTD. ,  Tokushima University

Inventor： Tohru Tanaka ,  Motowo Nakajima ,  Kiwamu Takahashi ,  Takuya Ishii ,  Hiroshi Kido ,  Junji Chida ,  Kazuhiko Yamane

IPC: A61K31/197 ,  A61K33/26 ,  A61K31/194 ,  A61K45/06

CPC classification number: A61K31/197 ,  A61K31/194 ,  A61K33/26 ,  A61K45/06 ,  A61K2300/00

Abstract: Provided is a prophylactic/therapeutic agent for influenza viral infection that is effective not only before and at an early stage of infection with influenza virus but also at an intermediate or late stage of the infection and is highly safe for human bodies. A prophylactic/therapeutic drug for influenza viral infection comprising, as active ingredients, 5-aminolevulinic acid (5-ALA), a derivative thereof or a salt of the 5-ALA or the derivative, and an iron compound is prepared. This prophylactic/therapeutic agent can be used for ameliorating (preventing) depression in food consumption, water consumption and body weight, for ameliorating (decreasing) increase in ketone body levels in blood that may otherwise cause ketosis, for ameliorating (preventing) depression in ATP levels in blood, or for ameliorating (increasing) a survival rate and depression in a body surface temperature.

Abstract translation: 提供了用于流感病毒感染的预防/治疗剂，其不仅在感染流感病毒之前和早期阶段都有效，而且在感染的中间或晚期也是有效的，并且对人体是高度安全的。 制备流感病毒感染的预防/治疗药物，其包含作为活性成分的5-氨基乙酰丙酸（5-ALA），其衍生物或5-ALA或其衍生物的盐和铁化合物。 这种预防/治疗剂可用于改善（预防）食物消耗，饮水和体重中的抑制，以改善（减少）可能引起酮症的血液中酮体水平升高（降低），以改善（预防）ATP抑制 血液中的水平，或改善（增加）体表温度的存活率和抑郁症。